BioCentury
ARTICLE | Clinical News

Depomed's DM-1992 meets Phase II Parkinson's endpoint

November 8, 2012 1:04 AM UTC

Depomed Inc. (NASDAQ:DEPO) said twice-daily DM-1992 met the primary endpoint vs. generic immediate-release (IR) carbidopa-levodopa dosed as needed (average of 4.8 doses/day) in a Phase II trial to treat Parkinson's disease (PD). DM-1992 significantly reduced mean daily "off" time during waking hours in which patients experienced symptoms of their PD from baseline to day 10 by 5.3% vs. a 1% increase for IR carbidopa/levodopa (p=0.047). The use of IR carbidopa/levodopa as rescue medication was higher in the DM-1992 arm vs. IR carbidopa/levodopa arm (1.3 vs. 0.2 mean daily doses). Patients who experienced an "off" state for more than two hours were permitted to take rescue medication. The open-label, crossover, U.S. Phase II trial enrolled 34 advanced PD patients with motor fluctuations. ...